David S. Friedman, M.D., M.P.H., Ph.D., is the Alfred Sommer Professor at the Wilmer Eye Institute of Johns Hopkins University School of Medicine and is also a professor in the Department of International Health at Johns Hopkins Bloomberg School of Public Health. He is the director of the Dana Center for Preventive Ophthalmology, a leader in global and domestic research on blindness prevention and the only World Health Organization collaborating center in the United States.
Dr. Friedman is world renowned for his contributions to the study of the mechanisms, epidemiology and prevention of angle-closure glaucoma. He has also made important contributions in the area of medication adherence and was the principal investigator in the first trial to show that an intervention can successfully improve patient use of eye medicines. He is a highly valued glaucoma specialist and cataract surgeon, receiving referrals from the region and overseas. His current research in angle-closure glaucoma is being conducted through clinical trials in south China, where it is very common. He is fluent in Mandarin, proficient in Medical Spanish and speaks some Indonesian.
Dr. Friedman is the recipient of various awards from the National Institutes of Health, Research to Prevent Blindness and American Geriatric Society. He has also obtained substantial funding to support research in patient adherence to glaucoma medications. He co-edited a definitive book on angle-closure glaucoma and has published nearly 150 articles. He serves on the editorial boards of Ophthalmology and the Journal of Glaucoma, plays a leadership role in the World Glaucoma Association and the American Glaucoma Society, and recently became the senior ophthalmologist for Helen Keller International, a large non-profit organization dedicated to alleviating blindness worldwide.